SCHEMBL15436121

SCHEMBL15436121

CCCCCCCO[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
DNM1 Q05193 1/20 0.35
MGAM O43451 2/20 0.34
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP2D6 P10635 2/20 0.34
SPHK1 Q9NYA1 1/20 0.34
GMNN O75496 1/20 0.34
POLB P06746 1/20 0.34
THPO P40225 1/20 0.34
MTOR P42345 1/20 0.34
BLM P54132 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700267 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL17047313 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL17459233 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL9214310 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL2783730 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL11168279 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL5795950 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL15648022 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL21645278 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1
SCHEMBL19435044 1.00 USP2 (0.40) USP2ALDH1A1CNR1CNR2DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559577-B2 Chemical functionalization of cellulosic materials with diazo compounds Centre National de la Recherche Scientifique—CNRS- (FR) 2026-02-24 US disclosed
US-20230183383-A1 CHEMICAL FUNCTIONALIZATION OF CELLULOSIC MATERIALS WITH DIAZO COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) 2023-06-15 US disclosed
EP-4153638-A1 CHEMICAL FUNCTIONALIZATION OF CELLULOSIC MATERIALS WITH DIAZO COMPOUNDS Centre National de la Recherche Scientifique (CNRS) (FR) 2023-03-29 EP disclosed
WO-2021233959-A1 CHEMICAL FUNCTIONALIZATION OF CELLULOSIC MATERIALS WITH DIAZO COMPOUNDS UNIVERSITE DE NANTES (FR) 2021-11-25 WO disclosed
EP-3307733-B1 MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS VERTEX PHARMA (US) 2021-10-20 EP disclosed
CN-107849031-B Mannose derivatives for the treatment of bacterial infections 沃泰克斯药物股份有限公司 2021-07-27 CN disclosed
EP-2900678-B1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG CENTRE NAT RECH SCIENT (FR) 2020-09-02 EP disclosed
CN-111423479-A Compounds and methods for treating bacterial infections 华盛顿大学 2020-07-17 CN disclosed
US-10543223-B2 Mannose derivatives useful for treating pathologies associated with adherent E. coli ENTEROME (FR) 2020-01-28 US disclosed
US-10407414-B2 Mannose derivatives for treating bacterial infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-09-10 US disclosed
US-20180244658-A1 Mannose Derivatives for Treating Bacterial Infections VERTEX PHARMACEUTICALS INCORPORATED 2018-08-30 US disclosed
US-20180235991-A1 MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI NANTES UNIVERSITE (FR) 2018-08-23 US disclosed
EP-3331893-A1 MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI Enterome (FR) 2018-06-13 EP disclosed
EP-3307733-A1 MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2018-04-18 EP disclosed
WO-2017021549-A1 MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI ENTEROME (FR) 2017-02-09 WO disclosed
WO-2016199105-A1 MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-15 WO disclosed
EP-2900678-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2015-08-05 EP disclosed
US-20150210781-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG NANTES UNIVERSITE (FR) 2015-07-30 US disclosed
WO-2014016361-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-01-30 WO disclosed
EP-2690105-A1 Mannose derivatives, a process for preparing the same and their uses as a drug Centre National De La Recherche Scientifique (FR) 2014-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407414-B2 Mannose derivatives for treating bacterial infections MANBA, MAN2A1, MPDU1 USP2 2963/4885ALDH1A1 2161/4885CNR1 1432/4885
US-20180235991-A1 MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI FPR3, CCR3, RXFP3 USP2 3247/4885ALDH1A1 2484/4885CNR1 322/4885
US-12559577-B2 Chemical functionalization of cellulosic materials with diazo compounds ILK, MGAM, LPO USP2 3117/4885ALDH1A1 663/4885CNR1 3344/4885
US-20180244658-A1 Mannose Derivatives for Treating Bacterial Infections MANBA, MAN2A1, MPDU1 USP2 2963/4885ALDH1A1 2161/4885CNR1 1432/4885
US-10543223-B2 Mannose derivatives useful for treating pathologies associated with adherent E. coli FPR3, CCR3, RXFP3 USP2 3247/4885ALDH1A1 2484/4885CNR1 322/4885
US-20150210781-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG MANBA, MAN2A1, MAN2B2 USP2 2525/4885ALDH1A1 2762/4885CNR1 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.